Clinical Trials Sponsored by Acesion Pharma

Total 9022 results

Alexion Pharmaceuticals

Withdrawn

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Alexion Pharmaceuticals

Terminated

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Warm Autoimmune Hemolytic Anemia

United States, Jordan
Alexion Pharmaceuticals

Terminated

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Pemphigus | Pemphigus Vulgaris | Pemphigus Foliaceus

United States
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

Spain, Germany, Italy, United States, Croatia, Canada, Russian Federation, Denmark, United Kingdom, Belgium, Mexico, Australia, Netherlands, Brazil, Turkey
Alexion Pharmaceuticals

Terminated

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

United Kingdom, Finland, United States, Italy
Alexion Pharmaceuticals

Completed

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Refractory Generalized Myasthenia Gravis

Korea, Republic of, United States, Spain, Canada, Netherlands, Belgium, Czechia, Denmark, Italy, Australia, Finland, Turkey, Germany, Greece, Brazil, Argentina, Japan, United Kingdom, Hungary, France, Sweden
Alexion Pharmaceuticals

Completed

Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada, United Arab Emirates, United Kingdom
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Canada
Alexion Pharmaceuticals

Completed

Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

Hypophosphatasia

United States, United Arab Emirates, United Kingdom
Alexion Pharmaceuticals

Completed

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Wolman Disease | Lysosomal Acid Lipase Deficiency

United Kingdom, France, United States, Egypt, Ireland
Alexion Pharmaceuticals

Terminated

Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

MPS IIIB (Sanfilippo B Syndrome)

Spain, United States, Brazil, United Kingdom, Portugal, Italy
Alexion Pharmaceuticals

Completed

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | LAL-Deficiency | Cholesterol Ester Storage Disease (CESD)

France, United Kingdom, United States, Canada, Czechia
Alexion Pharmaceuticals

Terminated

A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously (CL01-T)

Mucopolysaccharidosis III, Type B (MPS IIIB) | Sanfilippo B

United Kingdom
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals

Terminated

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Antibody Mediated Rejection

United States, Germany, Italy, France, United Kingdom, Spain, Sweden, Australia, Netherlands, Norway
Alexion Pharmaceuticals

Terminated

Screening for Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

United States
Alexion Pharmaceuticals

Completed

Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan

Hypophosphatasia
Alexion Pharmaceuticals

Terminated

aHUS Observational Long Term Follow-Up (LTFU)

Atypical Hemolytic Uremic Syndrome

France, Canada, United States, Belgium, Italy, United Kingdom, Netherlands, Australia, Austria, Germany, Sweden, Switzerland
Alexion Pharmaceuticals

Completed

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Coronary Artery Bypass Graft | Cardio-pulmonary Bypass

United States, Canada
Alexion Pharmaceuticals

Completed

Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging

MPS IIIB (Sanfilippo B Syndrome)

United Kingdom
Alexion Pharmaceuticals

No longer available

An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) (aHUS)

Atypical Hemolytic Uremic Syndrome

Canada, United Kingdom, France, Germany, Sweden, Netherlands, Italy
Alexion Pharmaceuticals

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Atypical Hemolytic-Uremic Syndrome

United Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
Alexion Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

Healthy Subjects

United States
Alexion Pharmaceuticals

Completed

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Hemoglobinuria, Paroxysmal

United States, United Kingdom, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland
Aetion, Inc.

Active, not recruiting

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

COVID-19

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Hepatitis C

United States, Belgium
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Human Immunodeficiency Virus (HIV)-1 Infection

United States, Spain, Germany, Dominican Republic
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

Bulgaria, Former Yugoslavia
Ascension Health
Medtronic

Recruiting

Physiologic Pacing for Symptomatic First-Degree Heart Block

Symptomatic First-degree Heart Block

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Neuromyelitis Optica Spectrum Disorder | NMOSD | AQP4+ NMOSD

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

China, United States, Spain, United Kingdom, Korea, Republic of, Italy, Germany, Japan, Brazil, France, Netherlands, Taiwan, Turkey, Israel, Poland, Austria, Denmark, Portugal, Canada, Serbia, Argentina, Switzerland
Alexion Pharmaceuticals, Inc.

Completed

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

Acute Intracranial Hemorrhage

Canada, Denmark, Italy, Netherlands, Spain, United States, Belgium, Switzerland, Germany, Hungary, Russian Federation, Czechia, France, United Kingdom, Israel, Austria, Norway, Latvia, Finland, Poland, Sweden, Portugal, Greece, Lithuania
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Alexion Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome

Guillain-Barre Syndrome

Japan
Alexion Pharmaceuticals, Inc.

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Taiwan, Thailand, Korea, Republic of, Japan, Malaysia, Brazil, Germany, Israel, Czechia, Netherlands, Greece, United Kingdom, Canada, Poland
Alexion Pharmaceuticals, Inc.

Completed

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

Healthy

United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Myasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile Form

United States, Japan, Netherlands
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

AL Amyloidosis

United States, Germany, Spain, Russian Federation, France, Korea, Republic of, Poland, Israel, Netherlands, Japan, Belgium, Greece, Switzerland, Australia, Austria, Brazil, Canada, China, Czechia, Italy, United Kingdom
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis | Myasthenia Gravis

United States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
Portola Pharmaceuticals

Terminated

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

Bleeding

United States
Portola Pharmaceuticals

Completed

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

Healthy Subjects
Portola Pharmaceuticals

Completed

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI (INNOVATE-PCI)

Percutaneous Coronary Intervention

United States, Austria, Canada, Germany, Poland
Portola Pharmaceuticals

Completed

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin (EXPLORE-Xa)

Atrial Fibrillation

United States, Canada
Portola Pharmaceuticals

Completed

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Thromboembolism

Canada
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

Healthy Volunteers

United States
AZ Delta
Alexion

Completed

Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones

Thrombosis | PNH

Belgium
Boston University
Actelion

Terminated

Macitentan in Pulmonary Hypertension of Sickle Cell Disease (MENSCH)

Sickle Cell Disease | Pulmonary Hypertension

United States

Clinical Trials Sponsored by Acesion Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations